Silverarc Capital Management, LLC Leap Therapeutics, Inc. Transaction History

Silverarc Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 25, 2022	SELL	$0.96 - $1.91 $990,876 - $1.97 Million	-1,032,163 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$1.6 - $3.35 $29,598 - $61,971	18,499 Added 1.82%	1,032,163 $1.81 Million
Q4 2021 Feb 14, 2022	BUY	$2.08 - $3.65 $818,821 - $1.44 Million	393,664 Added 63.49%	1,013,664 $3.28 Million
Q3 2021 Nov 15, 2021	BUY	$1.35 - $4.01 $837,000 - $2.49 Million	620,000 New	620,000 $2.49 Million
Q2 2021 Aug 16, 2021	SELL	$1.48 - $1.92 $444,000 - $576,000	-300,000 Closed	0 $0

Q1 2021 May 18, 2021	BUY	$1.82 - $3.01 $45,500 - $75,250	25,000 Added 9.09%	300,000 $570,000
Q4 2020 Feb 16, 2021	BUY	$1.49 - $2.37 $409,750 - $651,750	275,000 New	275,000 $619,000

265K

Ticker LPTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,021,400
Market Cap $198M
Description
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate can...

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Silverarc Capital Management, LLC with notifications on news.